| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Short Communication |
¶
From the Departments of Medicine* and Surgery, S.A. Localio Laboratory for Surgical Research, the Department of Pathology, The Veterans Administration New York Harbor Healthcare System, New York University Cancer Institute,¶ New York University School of Medicine, New York, New York
Recent reports indicate that circulating endothelial progenitor cells (EPCs) may be recruited to sites of neovascularization where they differentiate into endothelial cells (EC). As we have previously demonstrated that adenosine A2A agonists promote neovascularization in wounds, we sought to determine whether adenosine A2A receptor agonist-augmented wound healing involves vessel sprouting (angiogenesis) or EPC recruitment (vasculogenesis) or both. Four weeks after bone marrow reconstitution from donor FVB/N Tie2GFP transgenic mice, two full-thickness excisional wounds were performed on the dorsum of FVB/N wild-type mice and treated with either an A2A receptor agonist (CGS-21680) or vehicle alone. Vessel density, as measured by CD31 staining, and density of EPC-derived vessels, as measured by GFP expression, were quantified in a blinded fashion using two-color fluorescence microscopy. We observed nearly a threefold increase in CD31-positive vessels and a more than 10-fold increase in GFP-positive cells in A2A agonist-treated 3-day old wounds, but by 6 days after wounding the differences between A2A agonist-treated and vehicle-treated wounds were no longer statistically significant. In conclusion, this is the first evidence that an exogenous agent such as an adenosine A2A receptor agonist increases neovascularization in the early stages of wound repair by increasing both EPC recruitment (vasculogenesis) and local vessel sprouting (angiogenesis).
This article has been cited by other articles:
 |
|
 |
|
  P. Fernandez, S. Trzaska, T. Wilder, L. Chiriboga, M. R. Blackburn, B. N. Cronstein, and E. S. L. Chan Pharmacological Blockade of A2A Receptors Prevents Dermal Fibrosis in a Model of Elevated Tissue Adenosine Am. J. Pathol., June 1, 2008; 172(6): 1675 - 1682. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ryzhov, N. V. Solenkova, A. E. Goldstein, M. Lamparter, T. Fleenor, P. P. Young, J. P. Greelish, J. G. Byrne, D. E. Vaughan, I. Biaggioni, et al. Adenosine Receptor-Mediated Adhesion of Endothelial Progenitors to Cardiac Microvascular Endothelial Cells Circ. Res., February 15, 2008; 102(3): 356 - 363. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Iijima, T. Kunieda, S. Yamaguchi, H. Kamigaki, I. Fujii-Taira, K. Sekimizu, T. Kubo, S. Natori, and K. J. Homma The Extracellular Adenosine Deaminase Growth Factor, ADGF/CECR1, Plays a Role in Xenopus Embryogenesis via the Adenosine/P1 Receptor J. Biol. Chem., January 25, 2008; 283(4): 2255 - 2264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Macedo, G. Pinhal-Enfield, V. Alshits, G. Elson, B. N. Cronstein, and S. J. Leibovich Wound Healing Is Impaired in MyD88-Deficient Mice: A Role for MyD88 in the Regulation of Wound Healing by Adenosine A2A Receptors Am. J. Pathol., December 1, 2007; 171(6): 1774 - 1788. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Auchampach Adenosine Receptors and Angiogenesis Circ. Res., November 26, 2007; 101(11): 1075 - 1077. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kumin, M. Schafer, N. Epp, P. Bugnon, C. Born-Berclaz, A. Oxenius, A. Klippel, W. Bloch, and S. Werner Peroxiredoxin 6 is required for blood vessel integrity in wounded skin J. Cell Biol., November 19, 2007; 179(4): 747 - 760. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. W. Jackson, T. Hoshi, Y. Wu, X. Sun, K. Enjyoji, E. Cszimadia, C. Sundberg, and S. C. Robson Disordered Purinergic Signaling Inhibits Pathological Angiogenesis in Cd39/Entpd1-Null Mice Am. J. Pathol., October 1, 2007; 171(4): 1395 - 1404. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Merighi, A. Benini, P. Mirandola, S. Gessi, K. Varani, C. Simioni, E. Leung, S. Maclennan, P. G. Baraldi, and P. A. Borea Caffeine Inhibits Adenosine-Induced Accumulation of Hypoxia-Inducible Factor-1{alpha}, Vascular Endothelial Growth Factor, and Interleukin-8 Expression in Hypoxic Human Colon Cancer Cells Mol. Pharmacol., August 1, 2007; 72(2): 395 - 406. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Patschan, S. Patschan, G. G. Gobe, S. Chintala, and M. S. Goligorsky Uric Acid Heralds Ischemic Tissue Injury to Mobilize Endothelial Progenitor Cells J. Am. Soc. Nephrol., May 1, 2007; 18(5): 1516 - 1524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Mohsenin, M. D. Burdick, J. G. Molina, M. P. Keane, and M. R. Blackburn Enhanced CXCL1 production and angiogenesis in adenosine-mediated lung disease FASEB J, April 1, 2007; 21(4): 1026 - 1036. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kong, K. A. Westerman, M. Faigle, H. K. Eltzschig, and S. P. Colgan HIF-dependent induction of adenosine A2B receptor in hypoxia FASEB J, November 1, 2006; 20(13): 2242 - 2250. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Pardanaud and A. Eichmann Identification, emergence and mobilization of circulating endothelial cells or progenitors in the embryo Development, July 1, 2006; 133(13): 2527 - 2537. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. H. Adair Growth regulation of the vascular system: an emerging role for adenosine Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2005; 289(2): R283 - R296. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Frantz, K. A. Vincent, O. Feron, and R. A. Kelly Innate Immunity and Angiogenesis Circ. Res., January 7, 2005; 96(1): 15 - 26. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
